Evidence for a therapeutic benefit of IFNβ in NPC comes also from adults where patients treated with adjuvant IFNβ had a significant better outcome than patients being treated without IFNβ [11]. The gene discussed is IFNB1; the disease is nasopharyngeal carcinoma.